Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8WUA7
UPID:
TB22A_HUMAN
Alternative names:
-
Alternative UPACC:
Q8WUA7; B0QYI2; B0QYI3; B9A6M3; Q5TE47; Q6ZUH2; Q92680; Q9BVD6; Q9UGG0; Q9UGT2; Q9UGU6; Q9UH25; Q9Y4W5
Background:
TBC1 domain family member 22A plays a crucial role in cellular processes as a potential GTPase-activating protein for Rab family proteins. This function is pivotal for regulating intracellular membrane trafficking and dynamics.
Therapeutic significance:
Understanding the role of TBC1 domain family member 22A could open doors to potential therapeutic strategies. Its involvement in fundamental cellular mechanisms makes it a promising target for drug discovery.